Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:AKBA's Cash-to-Debt is ranked higher than
73% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:AKBA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AKBA' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: 12424.6
Current: No Debt
N/A
12424.6
Equity-to-Asset 0.12
NAS:AKBA's Equity-to-Asset is ranked lower than
99.99% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:AKBA: 0.12 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AKBA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.12 Max: 0.12
Current: 0.12
Interest Coverage No Debt
NAS:AKBA's Interest Coverage is ranked higher than
63% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AKBA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:AKBA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: -1.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -744.72
NAS:AKBA's Operating Margin % is ranked lower than
99.99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:AKBA: -744.72 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AKBA' s Operating Margin % Range Over the Past 10 Years
Min: -8889.9  Med: -8889.9 Max: -744.72
Current: -744.72
-8889.9
-744.72
Net Margin % -740.44
NAS:AKBA's Net Margin % is ranked lower than
99.99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:AKBA: -740.44 )
Ranked among companies with meaningful Net Margin % only.
NAS:AKBA' s Net Margin % Range Over the Past 10 Years
Min: -8843.45  Med: -8843.45 Max: -740.44
Current: -740.44
-8843.45
-740.44
ROE % -154.34
NAS:AKBA's ROE % is ranked lower than
82% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:AKBA: -154.34 )
Ranked among companies with meaningful ROE % only.
NAS:AKBA' s ROE % Range Over the Past 10 Years
Min: -154.34  Med: -94.01 Max: -51.66
Current: -154.34
-154.34
-51.66
ROA % -67.42
NAS:AKBA's ROA % is ranked lower than
76% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:AKBA: -67.42 )
Ranked among companies with meaningful ROA % only.
NAS:AKBA' s ROA % Range Over the Past 10 Years
Min: -365.24  Med: -61.26 Max: -47.82
Current: -67.42
-365.24
-47.82
ROC (Joel Greenblatt) % -7284.86
NAS:AKBA's ROC (Joel Greenblatt) % is ranked lower than
86% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:AKBA: -7284.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AKBA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -106220  Med: -24010.07 Max: -7284.86
Current: -7284.86
-106220
-7284.86
GuruFocus has detected 3 Warning Signs with Akebia Therapeutics Inc $NAS:AKBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AKBA's 30-Y Financials

Financials (Next Earnings Date: 2017-08-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AKBA Guru Trades in Q2 2016

Paul Tudor Jones 18,798 sh (+1.62%)
Steven Cohen Sold Out
Jim Simons 24,300 sh (-14.74%)
» More
Q3 2016

AKBA Guru Trades in Q3 2016

Jim Simons 151,800 sh (+524.69%)
Paul Tudor Jones 18,410 sh (-2.06%)
» More
Q4 2016

AKBA Guru Trades in Q4 2016

Jim Simons 208,600 sh (+37.42%)
Paul Tudor Jones 19,728 sh (+7.16%)
» More
Q1 2017

AKBA Guru Trades in Q1 2017

Jim Simons 386,267 sh (+85.17%)
Paul Tudor Jones 17,777 sh (-9.89%)
» More
» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RETA, NAS:ANIP, NAS:RARX, NAS:RGNX, NAS:CARA, NAS:PTCT, NAS:SGMO, NAS:VSAR, NAS:ANAB, NAS:CTMX, NAS:NDRM, NAS:CALA, NAS:INO, NAS:WVE, NAS:ACHN, NAS:PRTK, NAS:AUPH, NAS:NTLA, NAS:ACIU, OTCPK:SNBIF » details
Traded in other countries:AX9.Germany,
Headquarter Location:USA
Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics for patients based on hypoxia inducible factor, biology and the commercialization of these products for patients with renal disease.

Akebia Therapeutics Inc was incorporated under the laws of the state of Delaware in February 2007. The Company is a biopharmaceutical company focused on the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body and a potentially novel mechanism of treating anemia. Its product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to chronic kidney disease, or CKD, not requiring dialysis.

Ratios

vs
industry
vs
history
PB Ratio 17.96
AKBA's PB Ratio is ranked lower than
65% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. AKBA: 17.96 )
Ranked among companies with meaningful PB Ratio only.
AKBA' s PB Ratio Range Over the Past 10 Years
Min: 11.51  Med: 11.78 Max: 18.08
Current: 17.96
11.51
18.08
PS Ratio 26.26
AKBA's PS Ratio is ranked lower than
99.99% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. AKBA: 26.26 )
Ranked among companies with meaningful PS Ratio only.
AKBA' s PS Ratio Range Over the Past 10 Years
Min: 16.86  Med: 17.25 Max: 26.49
Current: 26.26
16.86
26.49
Price-to-Free-Cash-Flow 19.71
AKBA's Price-to-Free-Cash-Flow is ranked higher than
87% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. AKBA: 19.71 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AKBA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.65  Med: 12.94 Max: 19.87
Current: 19.71
12.65
19.87
Price-to-Operating-Cash-Flow 17.79
AKBA's Price-to-Operating-Cash-Flow is ranked higher than
88% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. AKBA: 17.79 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AKBA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.41  Med: 11.67 Max: 17.92
Current: 17.79
11.41
17.92
EV-to-EBIT -1.94
AKBA's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. AKBA: -1.94 )
Ranked among companies with meaningful EV-to-EBIT only.
AKBA' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.95  Med: -0.7 Max: -0.6
Current: -1.94
-1.95
-0.6
EV-to-EBITDA -1.94
AKBA's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. AKBA: -1.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKBA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.95  Med: -0.7 Max: -0.6
Current: -1.94
-1.95
-0.6
Current Ratio 1.91
AKBA's Current Ratio is ranked lower than
66% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. AKBA: 1.91 )
Ranked among companies with meaningful Current Ratio only.
AKBA' s Current Ratio Range Over the Past 10 Years
Min: 1.91  Med: 11.75 Max: 26.43
Current: 1.91
1.91
26.43
Quick Ratio 1.91
AKBA's Quick Ratio is ranked lower than
63% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. AKBA: 1.91 )
Ranked among companies with meaningful Quick Ratio only.
AKBA' s Quick Ratio Range Over the Past 10 Years
Min: 1.91  Med: 11.75 Max: 26.43
Current: 1.91
1.91
26.43
Days Sales Outstanding 591.68
AKBA's Days Sales Outstanding is ranked lower than
99.99% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. AKBA: 591.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKBA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 591.68  Med: 8042.6 Max: 8042.6
Current: 591.68
591.68
8042.6

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 23.55
AKBA's Price-to-Net-Cash is ranked lower than
71% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. AKBA: 23.55 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AKBA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 2.74 Max: 23.58
Current: 23.55
0
23.58
Price-to-Net-Current-Asset-Value 20.78
AKBA's Price-to-Net-Current-Asset-Value is ranked higher than
55% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. AKBA: 20.78 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AKBA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 2.69 Max: 20.81
Current: 20.78
0
20.81
Price-to-Tangible-Book 17.89
AKBA's Price-to-Tangible-Book is ranked lower than
57% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. AKBA: 17.89 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AKBA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.98  Med: 2.68 Max: 17.91
Current: 17.89
1.98
17.91
Price-to-Median-PS-Value 1.52
AKBA's Price-to-Median-PS-Value is ranked lower than
99.99% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. AKBA: 1.52 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AKBA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.52
Current: 1.52
0
1.52
Earnings Yield (Greenblatt) % -52.38
AKBA's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. AKBA: -52.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKBA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -173.54  Med: 0 Max: No Debt
Current: -52.38
-173.54
No Debt

More Statistics

Revenue (TTM) (Mil) $20.87
EPS (TTM) $ -4.05
Beta1.08
Short Percentage of Float4.95%
52-Week Range $7.00 - 15.88
Shares Outstanding (Mil)38.86

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 132 140 218
EPS ($) -3.24 -2.20 1.53
EPS without NRI ($) -3.24 -2.20 1.53
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to... May 24 2017
Four Stocks Moving On Both News And The Charts May 17 2017
Today's Research Reports on Stocks to Watch: Akebia Therapeutics and xG Technology May 17 2017
Why Akebia Therapeutics Stock Is Skyrocketing Today May 16 2017
Biotech Movers: Akebia, Editas, Novavax May 16 2017
Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius... May 16 2017
Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius... May 15 2017
Akebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact May 15 2017
Akebia Therapeutics reports 1Q loss May 09 2017
Akebia Announces First Quarter 2017 Financial Results May 09 2017
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) May 04 2017
Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : April 28, 2017 Apr 28 2017
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8% Apr 28 2017
4 Things To Know About Akebia's New Vadadustat Collaboration With Otsuka Pharma Apr 27 2017
Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : April... Apr 27 2017
Why Akebia Therapeutics Shares Soared 33.4% Today Apr 26 2017
Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy Apr 26 2017
Biotech Movers: Akebia Soars on Expanded Partnership With Otsuka Apr 26 2017
Akebia expands anemia drug pact with Japanese firm, lifting shares Apr 25 2017
Akebia shares jump on expanded anemia drug deal with Otsuka Apr 25 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat